Riders · Health and Human Services Commission · Article II: Health and Human Services

Texas Pharmaceutical Initiative (TPI)

Rider 124 in the 2026-27 Act, page II-85

2028-29 request. Health and Human Services Commission has asked to revise this rider. What it asked for. A request, not law.

Through the session

  1. 2024-25 Act Not in this version
  2. Introduced (Senate) New rider 93
  3. Introduced (House) New rider 92
  4. Senate substitute Unchanged rider 93
  5. House substitute Amended rider 92
  6. House passed Unchanged rider 92
  7. Conference Amended rider 124
  8. 2026-27 Act Unchanged rider 124

Pick any two steps to compare their wording.

What changed in the text

House passed → Conference: 1 passage changed.

Texas Pharmaceutical Initiative (TPI). (a) Full Time Equivalents (FTEs). The number of FTEs for Goal N, Texas Pharmaceutical Initiative, is 25.6 in each year of the biennium. (b) Unexpended Balances. (1) Any unexpended balances remaining on August 31, 2025, in Strategy O.1.1, Texas Pharmaceutical Initiative, in the 2024-25 biennium (estimated to be $0) are appropriated for the same purpose for the fiscal year beginning September 1, 2025, in Strategy N.1.1, Texas Pharmaceutical Initiative. (2) Any unexpended balances remaining on August 31, 2026, in Strategy N.1.1, Texas Pharmaceutical Initiative, are appropriated for the same purpose for the fiscal year beginning September 1, 2026, contingent upon TPI providing written notification to the Legislative Budget Board and the Office of the Governor at least 30 calendar days prior to making the transfer. (c) Texas Pharmaceutical Initiative Report. Out of funds appropriated above in Strategy N.1.1, Texas Pharmaceutical Initiative, TPI shall submit on a quarterly basis, within 30 calendar days of the end of each fiscal quarter, the following information to the Legislative Budget Board and the Office of the Governor: (1) Information on appropriated, budgeted, expended, and projected funds and FTEs, by strategy and method of finance from the previous fiscal quarter; (2) Narrative explanations of significant budget adjustments, ongoing budget issues, progress on active business plan operations, and other items as appropriate from the previous fiscal quarter; and (3) Any additional information requested by the Legislative Budget Board or the Office of the Governor. TPI shall submit the above information in an individual report prepared in a format specified by the Legislative Budget Board. (d) Sunset Contingency. Funds appropriated above for in fiscal years 2026 and 2027 for TPI are made contingent on the continuation of TPI by the Eighty-ninth Legislature, 2025. In the event that the agency is not continued, the funds appropriated for fiscal years 2026 and 2027, or as much thereof as may be necessary, are to be used to provide for the phase out of agency operations.

Removed words are struck through; added words are underlined. Sources: House passed · Conference.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium Not in this version
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) 93 New — Page II-94
Introduced (House)House Bill 1 as introduced (LBB recommended, House) 92 New — Page II-93
Senate substituteCommittee Substitute for Senate Bill 1 93 Unchanged New Page II-75
House substituteHouse Committee Substitute for Senate Bill 1 92 was 93 Amended New Page II-73
House passedSenate Bill 1 as passed the second house 92 Unchanged New Page II-73
ConferenceConference Committee Report for Senate Bill 1 124 was 92 Amended New Page II-84
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 124 Unchanged New Page II-85
Full text of each wording

Conference, 2026-27 Act

Source, page II-85

Texas Pharmaceutical Initiative (TPI).

(a) Full Time Equivalents (FTEs). The number of FTEs for Goal N, Texas Pharmaceutical Initiative, is 25.6 in each year of the biennium.

(b) Unexpended Balances.

(1) Any unexpended balances remaining on August 31, 2025, in Strategy O.1.1, Texas Pharmaceutical Initiative, in the 2024-25 biennium (estimated to be $0) are appropriated for the same purpose for the fiscal year beginning September 1, 2025, in Strategy N.1.1, Texas Pharmaceutical Initiative.

(2) Any unexpended balances remaining on August 31, 2026, in Strategy N.1.1, Texas Pharmaceutical Initiative, are appropriated for the same purpose for the fiscal year beginning September 1, 2026, contingent upon TPI providing written notification to the Legislative Budget Board and the Office of the Governor at least 30 calendar days prior to making the transfer.

(c) Texas Pharmaceutical Initiative Report. Out of funds appropriated above in Strategy N.1.1, Texas Pharmaceutical Initiative, TPI shall submit on a quarterly basis, within 30 calendar days of the end of each fiscal quarter, the following information to the Legislative Budget Board and the Office of the Governor:

(1) Information on appropriated, budgeted, expended, and projected funds and FTEs, by strategy and method of finance from the previous fiscal quarter;

(2) Narrative explanations of significant budget adjustments, ongoing budget issues, progress on active business plan operations, and other items as appropriate from the previous fiscal quarter; and

(3) Any additional information requested by the Legislative Budget Board or the Office of the Governor. TPI shall submit the above information in an individual report prepared in a format specified by the Legislative Budget Board.

(d) Sunset Contingency. Funds appropriated above in fiscal years 2026 and 2027 for TPI are made contingent on the continuation of TPI by the Eighty-ninth Legislature, 2025. In the event that the agency is not continued, the funds appropriated for fiscal years 2026 and 2027, or as much thereof as may be necessary, are to be used to provide for the phase out of agency operations.

Introduced (House), House substitute, House passed

Source, page II-73

Texas Pharmaceutical Initiative (TPI).

(a) Full Time Equivalents (FTEs). The number of FTEs for Goal N, Texas Pharmaceutical Initiative, is 25.6 in each year of the biennium.

(b) Unexpended Balances.

(1) Any unexpended balances remaining on August 31, 2025, in Strategy O.1.1, Texas Pharmaceutical Initiative, in the 2024-25 biennium (estimated to be $0) are appropriated for the same purpose for the fiscal year beginning September 1, 2025, in Strategy N.1.1, Texas Pharmaceutical Initiative.

(2) Any unexpended balances remaining on August 31, 2026, in Strategy N.1.1, Texas Pharmaceutical Initiative, are appropriated for the same purpose for the fiscal year beginning September 1, 2026, contingent upon TPI providing written notification to the Legislative Budget Board and the Office of the Governor at least 30 calendar days prior to making the transfer.

(c) Texas Pharmaceutical Initiative Report. Out of funds appropriated above in Strategy N.1.1, Texas Pharmaceutical Initiative, TPI shall submit on a quarterly basis, within 30 calendar days of the end of each fiscal quarter, the following information to the Legislative Budget Board and the Office of the Governor:

(1) Information on appropriated, budgeted, expended, and projected funds and FTEs, by strategy and method of finance from the previous fiscal quarter;

(2) Narrative explanations of significant budget adjustments, ongoing budget issues, progress on active business plan operations, and other items as appropriate from the previous fiscal quarter; and

(3) Any additional information requested by the Legislative Budget Board or the Office of the Governor. TPI shall submit the above information in an individual report prepared in a format specified by the Legislative Budget Board.

(d) Sunset Contingency. Funds appropriated above for fiscal years 2026 and 2027 for TPI are made contingent on the continuation of TPI by the Eighty-ninth Legislature, 2025. In the event that the agency is not continued, the funds appropriated for fiscal years 2026 and 2027, or as much thereof as may be necessary, are to be used to provide for the phase out of agency operations.

Introduced (Senate), Senate substitute

Source, page II-75

Texas Pharmaceutical Initiative (TPI).

(a) Full Time Equivalents (FTEs). The number of FTEs for Goal N, Texas Pharmaceutical Initiative, is 25.6 in each year of the biennium.

(b) Unexpended Balances.

(1) Any unexpended balances remaining on August 31, 2025, in Strategy N.1.1, Texas Pharmaceutical Initiative, in the 2024-25 biennium (estimated to be $0) are appropriated for the same purpose for the fiscal year beginning September 1, 2025, in Strategy N.1.1, Texas Pharmaceutical Initiative.

(2) Any unexpended balances remaining on August 31, 2026, in Strategy N.1.1, Texas Pharmaceutical Initiative, are appropriated for the same purpose for the fiscal year beginning September 1, 2026, contingent upon TPI providing written notification to the Legislative Budget Board and the Office of the Governor at least 30 calendar days prior to making the transfer.

(c) Texas Pharmaceutical Initiative Report. Out of funds appropriated above in Strategy N.1.1, Texas Pharmaceutical Initiative, TPI shall submit on a quarterly basis, within 30 calendar days of the end of each fiscal quarter, the following information to the Legislative Budget Board and the Office of the Governor:

(1) Information on appropriated, budgeted, expended, and projected funds and FTEs, by strategy and method of finance from the previous fiscal quarter;

(2) Narrative explanations of significant budget adjustments, ongoing budget issues, progress on active business plan operations, and other items as appropriate from the previous fiscal quarter; and

(3) Any additional information requested by the Legislative Budget Board or the Office of the Governor. TPI shall submit the above information in an individual report prepared in a format specified by the Legislative Budget Board.

(d) Sunset Contingency. Funds appropriated above for fiscal years 2026 and 2027 for TPI are made contingent on the continuation of TPI by the Eighty-ninth Legislature, 2025. In the event that the agency is not continued, the funds appropriated for fiscal years 2026 and 2027, or as much thereof as may be necessary, are to be used to provide for the phase out of agency operations.